The Coalition for Epidemic Preparedness (CEPI) has awarded $4M to Novavax (NASDAQ:NVAX) to support the development of a COVID-19 vaccine. It is currently assessing multiple candidates in animal models.
The parties are in talks about additional funds to
support the company’s costs through Phase 1 (expected to begin in late
spring).
Novavax plans to use its proprietary Matrix-M adjuvant with its vaccine candidates to enhance immune responses.
Emergent BioSolutions (NYSE:EBS) will provide contract development and manufacturing services and will supply product through Phase 1 testing.
Shares up 17% premarket on light volume.
https://seekingalpha.com/news/3550033-novavax-up-17-premarket-on-advancement-of-coronavirus-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.